Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00495417|
Recruitment Status : Completed
First Posted : July 3, 2007
Last Update Posted : October 19, 2010
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer's Disease||Biological: AFFITOPE AD01 Biological: AFFITOPE AD01 adjuvanted||Phase 1|
Alzheimer's Disease (AD) is a devastating neurodegenerative disorder for which there is no cure.
Although the etiology of AD is not fully understood, recent research suggests that Aβ is central to the disease process. Consequently, approaches capable of removing Aβ from the brain, such as Aβ immunotherapy, are expected to possess disease-modifying potential. This view is supported by evidence gathered in mouse models of AD and studies involving AD patients.
Based on the view that active Aβ immunotherapy has disease-modifying potential both in animal models of AD and in patients, and on the knowledge gathered on the side-effects of Aβ-based immunotherapy encountered in humans, we designed a new generation of AD vaccines. Rather than using full length Aβ itself, we choose to use mimotopes of the N-terminal end of Aβ as the antigenic component of our vaccine (Mimotopes discovered by Affiris GmbH have been termed Affitopes). Mimotopes are peptides that functionally mimic the native antigenic epitope but do not show sequence identity to it. Thus, while being different from the original antigen, mimotopes are recognized by the same antibodies and, vice versa, are capable of inducing antibodies that cross-react with the original antigen itself. A major advantage offered by mimotopes is the lack of tolerance mechanisms that would prevent the induction of an immune response to it (as is the case with self peptides/proteins such as Aβ). To further increase the vaccine's safety profile, the length of the mimotope used was limited to preclude the elicitation of Aβ-specific T cells. Also, the mimotope used has been designed to generate antibodies directed exclusively to Aβ (i.e., they do not recognize parental APP itself). To provide helper epitopes for the generation of an antibody response, the mimotope is coupled to a carrier.
The trial is designed as a patient-blinded, single-center, randomized, controlled, parallel group, phase I clinical study of repeated once every 4 weeks administration by subcutaneous injection of Affitope AD01 alone or adsorbed to aluminum hydroxide in 24 patients with mild to moderate Alzheimer's Disease. In total, each patient will receive 4 immunizations. Patients will be randomized to receive Affitope AD01 alone or adsorbed to aluminum hydroxide. Each treatment group consists of 12 patients. For safety reasons, inclusion of patients will be done in a stepwise manner.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||24 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Randomized, Controlled, Parallel Group, Patient-blinded, Single-center Phase I Pilot Study to Assess Tolerability and Safety of Repeated s.c. Administration of a Single-dose of Affitope AD01 Applied With or Without Adjuvant to Patients With Mild to Moderate Alzheimer's Disease|
|Study Start Date :||July 2007|
|Actual Primary Completion Date :||August 2009|
|Actual Study Completion Date :||August 2009|
|Active Comparator: 1||
Biological: AFFITOPE AD01
|Active Comparator: 2||
Biological: AFFITOPE AD01 adjuvanted
- Tolerability [ Time Frame: One year ]
- Immunological and clinical efficacy (evaluated in explorative manner) [ Time Frame: One year ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||50 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Diagnosis of probable Alzheimer's disease based on the NINCDS/ADRDA criteria.
- Assessing the severity of Alzheimer's disease of mild to moderate degree by the Mini Mental State Examination (MMSE 16-26)
- Hachinski Ischemia Scale ≤ 4.
- Magnetic Resonance Imaging scan (MRI) of brain consistent with diagnosis of AD.
- Informed consent capability (as determined by an independent neurologist)
- Written informed consent signed and dated by the patient or the patient's legal representative and the caregiver.
- Age >50 years.
- Availability of a partner/caregiver knowing the patient and being able to accompany the patient to the visits and being available for the telephone interviews.
- Adequate visual and auditory acuity to allow neuropsychological testing.
- Female patients of childbearing potential using a medically accepted contraceptive method.
- AD therapies on stable doses for at least 3 months prior to Visit 1 and during the entire trial period.
- Stable doses of all other medications for at least 30 days prior to Visit 1 if considered relevant by the investigator.
- Pregnant women.
- Sexually active women of childbearing potential not using a medically accepted birth control method.
- Presence or history of allergy to components of the vaccine.
- Contraindication for MRI imaging.
- Operation (under general anaesthesia) within 3 months prior to study entry and scheduled elective operation during the whole study period.
- Participation in another clinical trial.
- History of questionable compliance to visit schedule; patients not expected to complete the clinical trial.
- Prior and/or current treatment with experimental immunotherapeutics including IVIG or vaccines for AD.
- Prior and/or current treatment with immunosuppressive drugs, concurrent treatment with beta-blockers.
- History and/or presence of autoimmune disease.
- Recent (≤3 years since last specific treatment) history of cancer (Exceptions: basal cell carcinoma, intraepithelial cervical neoplasia).
- Major psychiatric disorder (e.g. schizophrenia), if considered relevant by the investigator.
- Active infectious disease (e.g., Hepatitis B, C).
- Presence and/or history of Immunodeficiency (e.g., HIV).
- Significant neurological disease other than AD.
- Significant systemic illness.
- History of stroke or seizure.
- Change in dose of standard treatments for AD within 3 months prior to visit 1.
- Change in dose of other previous and current medications within the last 30 days prior to visit 1, if considered relevant by the investigator.
- Alcoholism or substance abuse within the past year (alcohol or drug intoxication).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00495417
|Department of Clinical Pharmacology, Medical University of Vienna|
|Vienna, Austria, 1090|
|Principal Investigator:||Markus Müller, UnivProf.Dr.||Medical University of Vienna|
|Responsible Party:||Affiris GmbH|
|Other Study ID Numbers:||
EUDRACT Number 2006-007063-90
|First Posted:||July 3, 2007 Key Record Dates|
|Last Update Posted:||October 19, 2010|
|Last Verified:||September 2009|
Central Nervous System Diseases
Nervous System Diseases